Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 1, 2023
EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic...
-
May 16, 2023
EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held...
-
May 15, 2023
EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16th at 8:30 AM EST NEW YORK, May 15, 2023 /PRNewswire/...
-
May 11, 2023EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett's Esophagus
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
May 5, 2023Conference Call and Webcast at 8:30AM Eastern Time
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
May 5, 2023Conference Call and Webcast at 8:30AM Eastern Time
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
Apr 25, 2023Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial ExcellencePAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
- Apr 19, 2023Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m. to 12:30 p.m. CDT.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
-
Apr 18, 2023Lucid's CLIA laboratory, which performs its EsoGuard test, operates within Noridian's jurisdiction
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Apr 17, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Mar 31, 2023Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Mar 14, 2023Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Mar 13, 20234Q22 and projected 1Q23 EsoGuard® test volume increases 8 and 36 percent sequentially and 288 and 300 percent annually.
Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM,...
-
Mar 3, 2023Conference Call and Webcast at 8:30AM Eastern Time
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Mar 3, 2023Conference Call and Webcast at 8:30AM Eastern Time
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
- Feb 28, 2023Remote patient monitoring of first cohort of cancer patients using VerisBox™ connected devices and Veris CCP smartphone app initiated
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
-
Feb 15, 2023Partners with San Antonio Fire Department to test nearly 400 firefighters for esophageal precancer during Firefighter Cancer Awareness Month over two weekends, averaging nearly 100 tests per day
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jan 17, 2023Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercialization efforts
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital...
-
Jan 11, 2023Companies to host Conference Call at 4:30 PM EDT on Tuesday, January 17, 2023
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors,...
-
Dec 22, 2022License option and joint R&D agreement seek to apply Novosound’s groundbreaking flexible thin-film ultrasound technology to intravascular imaging
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital...
-
Dec 15, 2022Executes first commercial contract with leading New Jersey oncology practice
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital...
-
Dec 8, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned...
-
Dec 1, 2022EsoCheck esophageal cell sampling procedure performed on 687 patients with 98% success rate
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Nov 15, 2022EsoGuard test volume shows steady sequential growth
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device,...
-
Nov 14, 2022EsoGuard test volume increased 28% sequentially and 436% annually
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned...